** Brokerage BMO Capital Markets says the inclusion of Vertex's VRTX.O non-opioid painkiller in tier 3 on two of insurer UnitedHealth's UNH.N approved drug lists is a modest headwind
** The tier 3 designation is reserved for "non-preferred" brand-name drugs that may have lower-cost options
** The drug, Journavx, will likely cost more than those on tier 1 or tier 2, which usually include low-cost generics or preferred drugs on patent
** Truly differentiated drugs with a tier 3 designation, such as Gilead's GILD.O Livdelzi and Roche's ROG.S Vabysmo, can still see strong uptake - BMO
** The designation will likely drive some patient access headwinds as VRTX looks to establish its offering as differentiated vs cheap alternatives - brokerage
** Twenty of 33 brokerages rate the stock "buy" or higher, 12 "hold" and one "sell" or lower; their median PT is $520
** VRTX fell 4.2% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.